Cargando…

Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients

Denosumab is reported to increase bone mineral density (BMD) among haemodialysis patients; however, hypocalcaemia is a serious adverse effect among chronic kidney disease (CKD) patients. Identifying which patients will show greater improvement in BMD is important. We enrolled 84 haemodialysis patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hori, Mayuko, Yasuda, Kaoru, Takahashi, Hiroshi, Kondo, Chika, Shirasawa, Yuichi, Ishimaru, Yuka, Sekiya, Yuka, Morozumi, Kunio, Maruyama, Shoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095701/ https://www.ncbi.nlm.nih.gov/pubmed/35546172 http://dx.doi.org/10.1038/s41598-022-12029-3

Ejemplares similares

The Impact of Liver Chemistries on Respiratory Failure among Hemodialysis Patients with COVID-19 during the Omicron Wave
por: Hori, Mayuko, et al.
Publicado: (2023)

The association of low serum magnesium levels with frailty among hemodialysis patients
por: Hori, Mayuko, et al.
Publicado: (2023)

Impact of serum magnesium and bone mineral density on systemic fractures in chronic hemodialysis patients
por: Hori, Mayuko, et al.
Publicado: (2021)

Non-A Blood Type Is a Risk Factor for Poor Cardio-Cerebrovascular Outcomes in Patients Undergoing Dialysis
por: Nakayama, Takafumi, et al.
Publicado: (2023)

Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters
por: Abe, Ichiro, et al.
Publicado: (2019)

Development of entrustable professional activities for residents rotating nephrology department in a Japanese university hospital: a Delphi study
por: Tanaka, Akihito, et al.
Publicado: (2021)

High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2018)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2016)

Association of Versican Turnover with All-Cause Mortality in Patients on Haemodialysis
por: Genovese, Federica, et al.
Publicado: (2014)

Persistence of Denosumab Therapy among Patients with Osteoporosis
por: Kobayashi, Kazuyoshi, et al.
Publicado: (2020)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Denosumab for Prevention of Acute Onset Immobilization‐Induced Alterations of Bone Turnover: A Randomized Controlled Trial
por: Wadiura, Lisa Irina, et al.
Publicado: (2022)

Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation
por: Gonzalez-Rodriguez, Elena, et al.
Publicado: (2018)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab
por: Regev, Ravit, et al.
Publicado: (2021)

Association of protein-energy wasting and inflammation status with mortality after coronary revascularisation in patients on haemodialysis
por: Kumada, Yoshitaka, et al.
Publicado: (2020)

Predicting employment status and subjective quality of life in patients with schizophrenia
por: Fujino, Haruo, et al.
Publicado: (2015)

Guided optimization of fluid status in haemodialysis patients
por: Machek, Petr, et al.
Publicado: (2010)

Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls
por: Li, Hengyuan, et al.
Publicado: (2020)

Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Drug holiday of high-dose denosumab and recovery from osteoclast inhibition using immunohistochemical investigation of 7 patients with medication-related osteonecrosis of the jaw undergoing segmental mandibulectomy
por: Sawada, Shunsuke, et al.
Publicado: (2023)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Relationship between plasma levels of sclerostin, calcium–phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients
por: Pietrzyk, Barbara, et al.
Publicado: (2018)

Fundamental research on surface electromyography analysis using discrete wavelet transform—an analysis of the central nervous system factors affecting muscle strength
por: Morozumi, Kazunori, et al.
Publicado: (2021)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Denosumab and muscle performance
por: Rolvien, Tim, et al.
Publicado: (2022)

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
por: McClung, M. R., et al.
Publicado: (2012)

Successful Introduction of Peritoneal Dialysis in an End-stage Renal Failure Patient with Idiopathic Aplastic Anemia
por: Suzuki, Yasuhiro, et al.
Publicado: (2020)

Metagenomic Shotgun Sequencing Analysis of Canalicular Concretions in Lacrimal Canaliculitis Cases
por: Okajima, Yukinobu, et al.
Publicado: (2021)

ATAD2 controls chromatin-bound HIRA turnover
por: Wang, Tao, et al.
Publicado: (2021)

Effects of denosumab treatment in chronic liver disease patients with osteoporosis
por: Saeki, Chisato, et al.
Publicado: (2020)

Comparison of Volume Status in Asymptomatic Haemodialysis and Peritoneal Dialysis Outpatients
por: Papakrivopoulou, Eugenia, et al.
Publicado: (2012)

Self-assessment of the health status and leisure activities of individuals on haemodialysis
por: Cunha, Alexandre Cardoso da, et al.
Publicado: (2022)

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone
por: Gaston, Czar Louie, et al.
Publicado: (2016)

Impact of ethical climate, moral distress, and moral sensitivity on turnover intention among haemodialysis nurses: a cross-sectional study
por: Kim, Haengsuk, et al.
Publicado: (2023)

Assessment of Strategies for Safe Drug Discontinuation and Transition of Denosumab Treatment in PMO—Insights From a Mechanistic PK/PD Model of Bone Turnover
por: Martínez-Reina, Javier, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f31d8125k2hglqbjacjl9t7pab